Pregnancy and lactation represent relative contraindications given absence of human safety data in these populations despite reassuring preclinical reproductive toxicology studies
There is no strong clinical evidence showing it can safely or effectively treat opioid withdrawal
Indeed, GLP-1R agonists suppress feeding behavior and decreased body weight via food-intake-regulatory brain regions including, but not limited to, the hypothalamus and the brainstem 13,56
Following in Medicare Part Ds footsteps, commercial insurers have traditionally covered GLP-1s only for Type 2 diabetes diagnoses, while largely denying coverage for weight loss
Frequency of polymorphisms did not deviate from Hardy-Weinberg equilibrium
Breastfeeding parents need an average of at least 500 additional calories daily, and GLP-1s can significantly decrease appetite and compromise energy and nutrition